Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics

• by Jinjin Li, Ziyi Yang, Liangzhong Liu, Fei Tang, Taihao Zheng, Chao Zhang, Yuan Peng, Zhenzhou Yang, Zhiming Zhou, Benxu Tan, Xiaoyue Zhang

• January 3, 2026

The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

• February 24, 2026

• 2 min

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

• by Kerri Miller

• April 6, 2026

• 2 min

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

• by Ignacio Melero, Bernhard Reis, Corinne Rusterholz, Alexandra Epp, Nicole A. Kratochwil, Chun Wu, Michael Hettich, Georgios Kazantzidis, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Julia Lostes Bardaji, Eduardo Castanon Alvarez, Carlos E. de Andrea, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Olivera Cirovic, Stefan N. Symeonides

• May 1, 2026